Literature DB >> 31098866

Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.

Yukie Fujimoto1, Takahiro Watanabe2, Akira I Hida3, Tomoko Higuchi1, Yoshimasa Miyagawa1, Hiromi Ozawa1, Ayako Bun1, Reiko Fukui1, Atsushi Sata1, Michiko Imamura1, Seiichi Hirota2, Yasuo Miyoshi4.   

Abstract

BACKGROUND: The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been established in breast cancers with estrogen receptor (ER)-negative and human epithelial growth factor receptor 2 (HER2)-negative or HER2-positive subtypes; however, its utility concerning the ER + /HER2 - subtype remains unclear.
METHODS: We evaluated the prognostic value of TILs by analyzing 717 invasive breast cancer operation cases. TILs were classified into three groups based on the proportion of area within the tumor: low ( < 10%), intermediate (10-50%), and high ( > 50%). Disease-free survival (DFS) and overall survival (OS) were calculated according to TIL levels.
RESULTS: Although there was no significant association between TIL levels and DFS or OS in all patients, high TILs were significantly associated with favorable DFS in Ki67-high (n = 238, p = 0.035) but not in Ki67-low (n = 470, p = 0.46) breast cancers. Multivariable analysis showed that high TILs were a significant and independent factor for DFS (HR 0.34; 95% CI 0.10-0.87; p = 0.023) among the Ki67-high group. In the ER + /HER2 - subtype, high-TILs showed favorable DFS in the Ki67-high group, although this was not statistically significant (p = 0.48); in contrast, unfavorable DFS was observed in the Ki67-low group (p = 0.027).
CONCLUSIONS: In Ki67-high breast cancers, high TILs were associated with favorable DFS, irrespective of subtype, but increasing TIL levels correlated with worse DFS in the Ki67-low group with the ER + /HER2 - subtype. These results highlight variation in TIL prognostic significance between Ki67-high and -low breast cancers, particularly for the ER + /HER2 - subtype.

Entities:  

Keywords:  Breast cancer; Ki67; Prognosis; Tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2019        PMID: 31098866     DOI: 10.1007/s12282-019-00977-0

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  4 in total

1.  Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy.

Authors:  Jing Zhang; Mustapha Abubakar; Pei Yuan; Hela Koka; Lei Guo; Xin Li; Xiaohong R Yang; Jianming Ying; Ning Lyu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

2.  Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.

Authors:  Zhao-Hua Gao; Cun-Xin Li; Ming Liu; Jia-Yuan Jiang
Journal:  BMC Cancer       Date:  2020-11-25       Impact factor: 4.430

3.  Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients.

Authors:  Jenny Pousette; Annelie Johansson; Carolin Jönsson; Tommy Fornander; Linda S Lindström; Hans Olsson; Gizeh Perez-Tenorio
Journal:  Cancers (Basel)       Date:  2022-10-04       Impact factor: 6.575

4.  Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.

Authors:  Signe Korsgaard Skriver; Maj-Britt Jensen; Ann Soegaard Knoop; Bent Ejlertsen; Anne-Vibeke Laenkholm
Journal:  Breast Cancer Res       Date:  2020-05-14       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.